Theravance Biopharma | Results Presentation Deck | 31 slides

Theravance Biopharma · 2023-02
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON

Slide inventory

31
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detailBeat · Current Reality (Pain)
02
other
Open slide detailBeat · Current Reality (Pain)
03
front_matter
Open slide detailBeat · Current Reality (Pain)
04
The slide uses a three-column layout to summarize corporate actions.summarize
Open slide detailBeat · Current Reality (Pain)
05
The slide uses a three-column layout to categorize corporate objectives.summarize
Open slide detailBeat · Current Reality (Pain)
06
summarize
Open slide detailBeat · Future Vision (Gain)
07
The slide uses two bar charts to illustrate growth trends over five quarters.analyze_data
Open slide detailBeat · Future Vision (Gain)Loop · Quick Win Big Bet
08
The slide uses a line chart for hospital share and a combo bar/line chart for community share to illustrate market penetration.analyze_data
Open slide detailBeat · Future Vision (Gain)
09
The slide outlines a clinical trial methodology using a timeline-based process flow.present_framework
Open slide detailBeat · Future Vision (Gain)
10
establish_context
Open slide detailBeat · Future Vision (Gain)
11
The slide uses a two-part structure: a top section for market sizing/segmentation and a bottom section for a competitive product comparison table.compare_peers
Open slide detailBeat · Future Vision (Gain)
12
The chart is a forest plot showing LS Mean differences with 95% confidence intervals.analyze_data
Open slide detailBeat · Future Vision (Gain)
13
The slide uses a timeline-based process diagram to illustrate the clinical trial structure.present_framework
Open slide detailBeat · Future Vision (Gain)
14
transition
Open slide detailBeat · Future Vision (Gain)
15
summarize
Open slide detailBeat · Future Vision (Gain)
16
The slide highlights specific cash flow activities like tax payments and share buybacks.summarize
Open slide detailBeat · Future Vision (Gain)
17
The chart shows a significant reduction in operating expenses from 2020 to 2023 guidance.analyze_data
Open slide detailBeat · Future Vision (Gain)
18
The table displays projected royalties and milestones for 2023-2026. The slide highlights the transition of royalty payments back to Theravance Biopharma startianalyze_data
Open slide detailBeat · Future Vision (Gain)
19
Uses a curved arrow diagram to represent a progression of value drivers.summarize
Open slide detailBeat · Future Vision (Gain)
20
Slide 20 of the presentation.other
Open slide detailBeat · The Bridge
21
Standard pharmaceutical product disclosure slide.other
Open slide detailBeat · The Bridge
22
Includes a footnote regarding market research methodology.establish_context
Open slide detailBeat · The Bridge
23
appendix
Open slide detailBeat · The Bridge
24
introduce_nominees
Open slide detailBeat · The Bridge
25
summarize
Open slide detailBeat · The Bridge
26
Includes abbreviations for COPD, nOH, and PTE in the footer.analyze_data
27
The funnel visualizes the drop-off from total diagnosed COPD patients to those currently on YUPELRI.size_opportunity
28
Slide lists specific academic abstracts presented at the 33rd International Symposium on the Autonomic Nervous System.other
29
The slide uses a before-after framework to justify a strategic pivot in clinical trial focus.present_solution
Open slide detailLoop · Before After
30
Includes a detailed table for Trelegy Ellipta royalties and milestones by year.analyze_data
31
Includes cash position, income statement items, and adjusted operating expenses excluding share-based compensation.analyze_data